Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas

Grayson A. Herrgott, James M. Snyder, Ruicong She, Tathiane M. Malta, Thais S. Sabedot, Ian Y. Lee, Jacob Pawloski, Guilherme G. Podolsky-Gondim, Karam P. Asmaro, Jiaqi Zhang, Cara E. Cannella, Kevin Nelson, Bartow Thomas, Ana C. deCarvalho, Laura A. Hasselbach, Kelly M. Tundo, Rehnuma Newaz, Andrea Transou, Natalia Morosini, Victor Francisco, Laila M. Poisson, Dhananjay Chitale, Abir Mukherjee, Maritza S. Mosella, Adam M. Robin, Tobias Walbert, Mark Rosenblum, Tom Mikkelsen, Steven Kalkanis, Daniela P. C. Tirapelli, Daniel J. Weisenberger, Carlos G. Carlotti, Jack Rock, Ana Valeria Castro () and Houtan Noushmehr ()
Additional contact information
Grayson A. Herrgott: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
James M. Snyder: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Ruicong She: Biostatistics, Henry Ford Health
Tathiane M. Malta: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Thais S. Sabedot: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Ian Y. Lee: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Jacob Pawloski: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Guilherme G. Podolsky-Gondim: University of Sao Paulo
Karam P. Asmaro: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Jiaqi Zhang: Biostatistics, Henry Ford Health
Cara E. Cannella: Biostatistics, Henry Ford Health
Kevin Nelson: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Bartow Thomas: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Ana C. deCarvalho: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Laura A. Hasselbach: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Kelly M. Tundo: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Rehnuma Newaz: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Andrea Transou: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Natalia Morosini: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Victor Francisco: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Laila M. Poisson: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Dhananjay Chitale: Henry Ford Health
Abir Mukherjee: Henry Ford Health
Maritza S. Mosella: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Adam M. Robin: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Tobias Walbert: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Mark Rosenblum: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Tom Mikkelsen: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Steven Kalkanis: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Daniela P. C. Tirapelli: University of Sao Paulo
Daniel J. Weisenberger: University of Southern California
Carlos G. Carlotti: University of Sao Paulo
Jack Rock: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Ana Valeria Castro: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health
Houtan Noushmehr: Omics Laboratory, Hermelin Brain Tumor Center, Henry Ford Health

Nature Communications, 2023, vol. 14, issue 1, 1-19

Abstract: Abstract Recurrence of meningiomas is unpredictable by current invasive methods based on surgically removed specimens. Identification of patients likely to recur using noninvasive approaches could inform treatment strategy, whether intervention or monitoring. In this study, we analyze the DNA methylation levels in blood (serum and plasma) and tissue samples from 155 meningioma patients, compared to other central nervous system tumor and non-tumor entities. We discover DNA methylation markers unique to meningiomas and use artificial intelligence to create accurate and universal models for identifying and predicting meningioma recurrence, using either blood or tissue samples. Here we show that liquid biopsy is a potential noninvasive and reliable tool for diagnosing and predicting outcomes in meningioma patients. This approach can improve personalized management strategies for these patients.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-41434-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-41434-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-41434-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().